Theravance Biopharma, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 88/100
What the filing says
On June 29, 2026, Theravance Biopharma announced a definitive acquisition agreement with Zymeworks Inc. at $17.00 per share in cash, plus a contingent value right (CVR) entitling shareholders to 80% of net proceeds from future ampreloxetine monetization over ten years. Transaction expected to close H2 2026 subject to shareholder approval. Company reported Q2 2026 revenue of $20.7M (11% YoY growth), $387.7M cash, no debt, and 35% YoY reduction in operating expenses.
Why this rating
Transformational exit event at $17/share plus CVR on $448.6M market cap. Eliminates going-concern uncertainty; ends strategic review. Material for equity holders.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.